Skip to main content

Table 2 Adverse events

From: A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Patients

1 mg/kg/day

2 mg/kg/day

Alternating

All n = 24

Cohort 1/Schedule A n = 10

Cohort 2 n = 8

Schedule B n = 6

Completed 1st cycle

7/10 (70 %)

5/8 (63 %)

5/6 (83 %)

17/24 (71 %)

Toxicities grade (%)

2

3

4

 

2

3

4

 

2

3

4

 

Rash

1

   

4

2

     

29.2

Diarrhea

3

1

  

1

      

20.8

Anorexia

5

2

  

4

   

4

  

62.5

Weight loss

1

1

      

2

  

16.7

Anxiety

1

          

4.2

Nausia

3

   

1

      

16.7

Vomiting

4

          

16.7

Fatigue

4

4

  

5

1

  

2

2

 

75.0

Muscle weakness

1

1

  

6

   

1

1

 

41.7

Myalgia

 

2

  

3

1

  

1

  

29.2

Rhabdomyolysis

      

1

    

4.2a

  1. aStudy related death
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us